Re: Fabry recap
As well he should. As SM has said it will be hard for the FDA to agree to AA absent a comparison to the SOC. Down playing without eliminating is facing facts
You may want to go back to see what MacKay actually said. It wasn't that the pathway was closed, but that achieving accelerated approval was no longer possible given the way the AVRO trial was designed.
Perhaps compensating him 20% more than SM over the past 2 years could have been better spent on trial design.
Facts can be inconvenient at times.